Autologous dendritic cells presenting patient-specific tumor-associated antigens and neoantigens (NeoAg-DC vaccine)

This therapeutic target represents a personalized immunotherapy approach where a patient's own dendritic cells (DCs) are engineered to prime the immune system against unique tumor markers. By utilizing patient-specific neoantigens—mutations found only in the tumor—and tumor-associated antigens (TAAs), the therapy minimizes off-target damage to healthy tissues while maximizing the specificity of the immune response. The dendritic cells act as the vehicle, processing these antigens and presenting them via Major Histocompatibility Complex (MHC) molecules to activate CD8+ and CD4+ T-cells (Rock et al., 2016). This process is designed to overcome the immunosuppressive environment of the tumor and establish long-term immunological memory. In clinical practice, this involves complex bioinformatics to identify mutations, followed by ex vivo DC maturation and antigen loading. While highly specific, the primary challenges include the high cost of individualized production and the potential for tumors to lose MHC expression, thereby escaping detection (Hu et al., 2021).

Other names

Personalized dendritic cell vaccineNeoantigen-pulsed autologous dendritic cellsTumor-antigen presenting dendritic cellsPatient-specific DC immunotherapyAutologous antigen-presenting cell therapy

Autologous dendritic cells are harvested from the patient and loaded (pulsed) with synthetic neoantigens or tumor lysates identified through genomic sequencing. These DCs are then re-infused into the patient, where they migrate to secondary lymphoid organs to present the tumor-specific peptides on MHC Class I and II molecules to naive T-cells. This interaction, supported by co-stimulatory signals, triggers the expansion of tumor-specific cytotoxic T-lymphocytes (CTLs) and helper T-cells that can recognize and eliminate malignant cells expressing those specific antigens (Sahin & Türeci, 2018; Banchereau & Steinman, 1998).